The addition of nivolumab to rucaparib did not lead to better progression-free survival than rucaparib monotherapy in patients with newly diagnosed, advanced, high-grade ovarian cancer (AHGOC), a new ...

BUFFALO GROVE, Ill., Dec. 19, 2025 /PRNewswire/ -- Tolmar, Inc. (Tolmar) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Rubraca® (rucaparib), ...

SAN FRANCISCO — For patients with metastatic castration-resistant prostate cancer (mCRPC) with a BRCA alteration whose disease had already progressed with an androgen receptor pathway inhibitor (ARPI) ...

SAN DIEGO -- Rucaparib (Rubraca) maintenance after first- or second-line chemotherapy improved progression-free survival (PFS) in patients with metastatic or recurrent endometrial cancer, a small ...

Learn everything you need to know about Rucaparib-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

The recommended dose of rucaparib drug is 600mg to be taken orally twice daily with food or on an empty stomach. Rucaparib should be continued till the drug becomes ineffective as demonstrated by the ...

BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the first presentation of data from the randomized, Phase 3 ARIEL4 study of Rubraca® (rucaparib) will take place ...

For patients with metastatic castration-resistant prostate cancer, treatment with rucaparib is associated with significantly longer duration of imaging-based progression-free survival compared with a ...

Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly diagnosed advanced ovarian cancer, a large randomized trial showed. In fact, ...

Rucaparib, the PARP inhibitor approved for the treatment of ovarian cancer, may have potential clinical benefit for patients with advanced pancreatic cancer and a BRCA1/2 mutation. The global, phase 2 ...

The rucaparib arm in this population (n=220) achieved statistical significance over the chemotherapy arm (n=105) for the primary endpoint of PFS with a hazard ratio of 0.64 (p=0.001). The median PFS ...